Investment Portfolio - Brandon Capital

We invest in great medical discoveries to build internationally competitive companies.

Show all
Drugs/Vaccines
Medical Devices
Platform/Diagnostics

Active
Clinical
Commercialisation
Exited
Pre-clinical

Allay Therapeutics

Combining non-opioid analgesics and biopolymers to deliver weeks of localised pain management

Aravax Pty Ltd

Developing peptide-based immunotherapies for food allergy treatment

AstronauTx

Cutting-edge biotech company founded to target neurodegenerative diseases by improving disrupted physiological processes leading to dementia.

Axelia Oncology

Biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response.

Azura Ophthalmics

Developing first-in-class ophthalmic keratolytics the first Pharmaceutical for the Treatment of Meibomian Gland Dysfunction

CatalYm

Reversing GDF-15-mediated immunosupression to induce anti-tumour responses

Certa Therapeutics

Certa Therapeutics novel drugs block a receptor that is a key driver of fibrosis (scarring) of the kidney and other organs. Certa is able to use genetic analysis to identify those patients that are most likely to benefit from therapy.

Cincera Therapeutics

A first in class orally available medicine for the treatment of fibrotic and inflammatory indications associated with type 2 diabetes and metabolic syndrome with an initial focus on liver fibrosis (NASH – non-alcoholic steatohepatitis).

Currus Biologics

Developing the next generation of CAR-T cell therapies to treat solid cancers

Denteric

Developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis)

EBR Systems

EBR Systems is a clinical stage company that is developing therapies for patients with cardiac rhythm diseases and heart failure using wireless cardiac stimulation.